Cortisol/NN
receptor/NN
resistance/NN
:/:
the/DT
variability/NN
of/IN
its/PRP$
clinical/JJ
presentation/NN
and/CC
response/NN
to/TO
treatment/NN
./.

Primary/JJ
(/(
partial/JJ
)/)
cortisol/NN
receptor/NN
resistance/NN
was/VBD
previously/RB
reported/VBN
in/IN
a/DT
total/NN
of/IN
7/CD
patients/NNS
and/CC
14/CD
asymptomatic/JJ
family/NN
members/NNS
./.
=====
Its/PRP$
occurrence/NN
is/VBZ
considered/VBN
to/TO
be/VB
extremely/RB
rare/JJ
./.
=====
In/IN
the/DT
present/JJ
study/NN
we/PRP
report/VBP
on/IN
6/CD
patients/NNS
(/(
2/CD
males/NNS
and/CC
4/CD
females/NNS
)/)
with/IN
the/DT
syndrome/NN
./.
=====
The/DT
first/JJ
male/JJ
patient/NN
presented/VBD
with/IN
mild/JJ
hypertension/NN
./.
=====
Hydrochlorothiazide/NN
therapy/NN
resulted/VBD
in/IN
life-threatening/JJ
hypokalemia/NN
./.
=====
The/DT
second/JJ
male/JJ
patient/NN
had/VBD
slight/JJ
hypertension/NN
without/IN
hypokalemia/NN
./.
=====
All/DT
four/CD
female/JJ
patients/NNS
presented/VBD
between/IN
the/DT
age/NN
of/IN
20-30/CD
yr/NN
with/IN
acne/NN
,/,
hirsutism/NN
,/,
and/CC
irregular/JJ
menstruations/NNS
./.
=====
Low/JJ
dose/NN
dexamethasone/NN
therapy/NN
(/(
1-1.5/CD
mg/day/NN
)/)
was/VBD
of/IN
clinical/JJ
benefit/NN
in/IN
these/DT
patients/NNS
./.
=====
All/DT
patients/NNS
showed/VBD
insufficient/JJ
suppression/NN
of/IN
serum/NN
cortisol/NN
concentrations/NNS
in/IN
the/DT
overnight/JJ
1-mg/JJ
dexamethasone/NN
test/NN
./.
=====
The/DT
diurnal/JJ
rhythm/NN
of/IN
ACTH/NN
and/CC
cortisol/NN
was/VBD
intact/JJ
,/,
albeit/IN
at/IN
an/DT
elevated/JJ
level/NN
./.
=====
There/EX
was/VBD
a/DT
normal/JJ
increase/NN
in/IN
ACTH/NN
,/,
cortisol/NN
,/,
and/CC
GH/NN
(/(
except/IN
in/IN
one/CD
obese/JJ
patient/NN
)/)
in/IN
response/NN
to/TO
insulin-induced/JJ
hypoglycemia/NN
,/,
while/IN
cortisol/NN
production/NN
was/VBD
elevated/JJ
in/IN
three/CD
patients/NNS
./.
=====
Circulating/VBG
adrenal/JJ
androgen/NN
levels/NNS
were/VBD
increased/VBN
in/IN
all/DT
patients/NNS
./.
=====
Glucocorticoid/NN
receptors/NNS
were/VBD
investigated/VBN
in/IN
a/DT
whole/JJ
cell/NN
dexamethasone/NN
binding/NN
assay/NN
in/IN
mononuclear/JJ
leukocytes/NNS
./.
=====
In/IN
the/DT
first/JJ
male/JJ
patient/NN
,/,
the/DT
number/NN
of/IN
receptors/NNS
was/VBD
very/RB
low/JJ
,/,
while/IN
the/DT
affinity/NN
was/VBD
lower/JJR
than/IN
that/DT
in/IN
controls/NNS
./.
=====
A/DT
lowered/JJ
affinity/NN
to/TO
dexamethasone/NN
was/VBD
found/VBN
in/IN
one/CD
female/JJ
patient/NN
,/,
while/IN
a/DT
lowered/JJ
number/NN
of/IN
receptors/NNS
was/VBD
found/VBN
in/IN
three/CD
patients/NNS
./.
=====
In/IN
the/DT
second/JJ
male/JJ
patient/NN
,/,
no/DT
abnormalities/NNS
were/VBD
found/VBN
./.
=====
As/IN
a/DT
bioassay/NN
for/IN
glucocorticoid/NN
action/NN
we/PRP
also/RB
measured/VBD
dexamethasone/NN
suppressibility/NN
of/IN
mitogen-stimulated/JJ
incorporation/NN
of/IN
[3H]thymidine/NN
in/IN
mononuclear/JJ
leukocytes/NNS
./.
=====
In/IN
the/DT
male/JJ
patient/NN
with/IN
normal/JJ
receptor/NN
status/NN
,/,
dexamethasone/NN
suppressibility/NN
of/IN
[3H]thymidine/NN
incorporation/NN
was/VBD
significantly/RB
lower/JJR
than/IN
that/DT
in/IN
healthy/JJ
controls/NNS
with/IN
respect/NN
to/TO
both/CC
maximal/JJ
suppression/NN
and/CC
IC50/NN
./.
=====
Partial/JJ
cortisol/NN
receptor/NN
resistance/NN
might/MD
be/VB
less/RBR
rare/JJ
than/IN
previously/RB
thought/VBN
./.
=====
In/IN
the/DT
six/CD
patients/NNS
presented/VBN
,/,
at/IN
least/JJS
three/CD
different/JJ
forms/NNS
can/MD
be/VB
recognized/VBN
./.
=====
Therapy/NN
with/IN
dexamethasone/NN
was/VBD
successful/JJ
in/IN
female/JJ
patients/NNS
with/IN
acne/NN
and/CC
hirsutism/NN
,/,
as/IN
the/DT
secondary/JJ
increase/NN
in/IN
the/DT
production/NN
of/IN
adrenal/JJ
androgens/NNS
was/VBD
effectively/RB
controlled/VBN
./.